MedTrace Logo

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07619339 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-06-11

No results posted yet for this study

Summary

The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.

Conditions

Interventions

DRUG

Tepotinib

Tepotinib will be administered at 225mg or 450mg oral daily continuously in every 3 week cycles.

DRUG

Ivonescimab

Ivonescimab is administered IV Q3W on Day 1 of each cycle. The total duration of ivonescimab treatment is up to 24 months.

Sponsors & Collaborators

Principal Investigators

  • Paul Paik, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-27
Primary Completion
2029-05-31
Completion
2029-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07619339 on ClinicalTrials.gov